STAT+: What a vote on Grail’s cancer detection test could mean for the company, patients, and regulators

9 publications, in the order they reported. The story spread over 74 hours 42 minutes. Words in highlight are ones the first headline did not use. All top stories · On NewsMarkets

Publications over time

Publications in order of reporting
#	Time (UTC)	After the first	Publication	Headline
1	2026-09-21 17:58	first	STAT (paywall)	STAT+: What a vote on Grail’s cancer detection test could mean for the company, patients, and regulators by Matthew Herper
2	2026-09-23 10:00	+40 hours 1 minute	NPR	Will FDA advisers recommend a multi-cancer blood test for approval? They'll vote by Yuki Noguchi
3	2026-09-23 12:39	+42 hours 40 minutes	MarketWatch (limited free articles)	FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow. by Jaimy Lee
4	2026-09-23 13:30	+43 hours 32 minutes	Quartz	FDA advisers are voting on Grail's multicancer blood test as Medicare coverage hangs in the balance by Cris Tolomia
5	2026-09-23 23:08	+53 hours 9 minutes	Scientific American (limited free articles)	Blood test for multiple cancers clears crucial hurdle on track to FDA approval
6	2026-09-23 23:13	+53 hours 14 minutes	Financial Times (paywall)	Cancer-screen blood test wins tepid support from US drug advisory panel
7	2026-09-24 10:05	+64 hours 6 minutes	South China Morning Post (limited free articles)	US regulators back multi-cancer blood test – but Hong Kong doctors remain cautious
8	2026-09-24 12:59	+67 hours	MedPage Today	FDA Advisors Recommend Galleri Multicancer Blood Test
9	2026-09-24 20:41	+74 hours 42 minutes	Inc.	This Controversial Cancer Test Just Passed a Key FDA Vote. Here’s Why It’s Dividing Experts by Chloe Aiello